JP2018111728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018111728A5 JP2018111728A5 JP2018080510A JP2018080510A JP2018111728A5 JP 2018111728 A5 JP2018111728 A5 JP 2018111728A5 JP 2018080510 A JP2018080510 A JP 2018080510A JP 2018080510 A JP2018080510 A JP 2018080510A JP 2018111728 A5 JP2018111728 A5 JP 2018111728A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- composition
- eculizumab
- administered
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361806687P | 2013-03-29 | 2013-03-29 | |
| US61/806,687 | 2013-03-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Division JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018111728A JP2018111728A (ja) | 2018-07-19 |
| JP2018111728A5 true JP2018111728A5 (https=) | 2018-12-27 |
| JP6505288B2 JP6505288B2 (ja) | 2019-04-24 |
Family
ID=50686201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Active JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| JP2018080510A Active JP6505288B2 (ja) | 2013-03-29 | 2018-04-19 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Active JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20160051673A1 (https=) |
| EP (2) | EP2978451B1 (https=) |
| JP (2) | JP6505079B2 (https=) |
| CA (1) | CA2897334A1 (https=) |
| ES (1) | ES2768648T3 (https=) |
| WO (1) | WO2014160958A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| US20170073399A1 (en) * | 2015-09-11 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| IL263657B2 (en) * | 2016-06-17 | 2025-12-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| EP3529619B1 (en) | 2016-10-19 | 2021-06-30 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5a in a sample |
| WO2018075758A1 (en) * | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
| KR102365871B1 (ko) * | 2017-01-31 | 2022-02-21 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| US11730792B2 (en) * | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| EP3597222A1 (en) * | 2018-07-16 | 2020-01-22 | Easemedcontrol R & D GmbH & Co KG | Treatment and diagnosis of unresolved inflammatory diseases |
| JP7653909B2 (ja) * | 2018-09-06 | 2025-03-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒト化抗ｃ５抗体とその利用 |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| EP3958901A4 (en) * | 2019-04-24 | 2023-07-19 | The Trustees of the University of Pennsylvania | BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES |
| WO2021154941A1 (en) * | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| WO2023064809A1 (en) * | 2021-10-12 | 2023-04-20 | Vanqua Bio, Inc. | Oligonucleotides for targeting complement c5 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US20030143204A1 (en) | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| WO2003022330A2 (en) | 2001-09-12 | 2003-03-20 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
| EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| WO2003093430A2 (en) | 2002-05-03 | 2003-11-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in preparing sirnas |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| WO2004015062A2 (en) | 2002-08-12 | 2004-02-19 | New England Biolabs, Inc. | Methods and compositions relating to gene silencing |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| HUE038239T2 (hu) | 2004-02-12 | 2018-10-29 | Archemix Llc | Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| NZ571791A (en) * | 2006-03-08 | 2012-03-30 | Archemix Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| JP2010533181A (ja) | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦα阻害剤の肺投与のための方法及び組成物 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| CA2766565A1 (en) | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| ES2615732T3 (es) * | 2010-03-01 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | Composiciones para tratar la enfermedad de Degos |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
-
2014
- 2014-03-28 EP EP14722916.5A patent/EP2978451B1/en not_active Revoked
- 2014-03-28 ES ES14722916T patent/ES2768648T3/es active Active
- 2014-03-28 JP JP2016505600A patent/JP6505079B2/ja active Active
- 2014-03-28 WO PCT/US2014/032209 patent/WO2014160958A1/en not_active Ceased
- 2014-03-28 US US14/779,605 patent/US20160051673A1/en not_active Abandoned
- 2014-03-28 EP EP18211716.8A patent/EP3473272A1/en not_active Withdrawn
- 2014-03-28 CA CA2897334A patent/CA2897334A1/en not_active Abandoned
-
2018
- 2018-04-19 JP JP2018080510A patent/JP6505288B2/ja active Active
-
2019
- 2019-05-29 US US16/425,402 patent/US20200023060A1/en not_active Abandoned
-
2023
- 2023-10-06 US US18/482,159 patent/US20240293540A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018111728A5 (https=) | ||
| JP2018193377A5 (https=) | ||
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| JP2016513097A5 (https=) | ||
| JP2017149726A5 (https=) | ||
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| JP2016540785A5 (https=) | ||
| JP2016503398A5 (https=) | ||
| EP4218813A3 (en) | High concentration anti-c5 antibody formulations | |
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| JP2012506448A5 (https=) | ||
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2006504795A5 (https=) | ||
| JP2013231087A5 (https=) | ||
| JP2017502074A5 (https=) | ||
| HRP20250972T1 (hr) | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak | |
| JP2018509388A5 (https=) | ||
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| JP2018529666A5 (https=) | ||
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| JP2018521007A5 (https=) | ||
| JP2020500864A5 (https=) | ||
| JP2022062153A5 (https=) | ||
| JP2013520448A5 (https=) | ||
| JP2014520892A5 (https=) |